Board Member
DBV Technologies S.A. (DBVT)Equibles does not estimate personal net worth.
Get an email with a short summary when DBV Technologies S.A. publishes a filing, an earnings call transcript or a press release.
Get DBVT alertsDaniel Tassé is recorded as CEO and Board Member at DBV Technologies S.A. (DBVT). The newest filing on record that lists Daniel Tassé as CEO and Board Member at DBV Technologies S.A. (DBVT) is dated May 11, 2026. The proxy statement of DBV Technologies S.A. reports total compensation of $1,472,146 for Daniel Tassé in fiscal 2024, including a base salary of $600,000. Disclosed compensation is on record for 5 fiscal years. Daniel Tassé has spoken on 14 earnings calls and 8 other investor events across 1 company, most recently for DBV Technologies S.A. on October 28, 2026. DBV Technologies S.A. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at DBV Technologies S.A. includes Michel de Rosen (Chairman), Virginie Boucinha (CFO and Chief Accounting Officer), Adora Ndu (Board Member) and 7 others.
“The work Kevin and his team are doing is a priority for the company and will remain so until the remedian efforts, the remediation efforts are completed. It's also very important that we not lose sight of the progress being made across DBV and would now like to provide an update on our toddler program.”
“As mentioned in our press release this afternoon, over the recent weeks, DBV has been having ongoing conversations and exchanges with the FDA regarding elements of our BLA with the intention of ensuring a complete, efficient, and timely review of our upcoming Biologics license application, the BLA, for the Viaskin…”
“As mentioned in our press release this afternoon, over the recent weeks, DBV has been having ongoing conversations and exchanges with the FDA regarding elements of our BLA with the intention of ensuring a complete, efficient, and timely review of our upcoming Biologics License Application, the BLA, for the Viaskin…”
“2026 is and will continue to be a pivotal year for DBV. We are working aggressively to transform the company into a commercial organization in anticipation of the potential approval of the Viaskin Peanut Patch for children age four through seven by the FDA.”
“As mentioned in our press release this afternoon, over the recent weeks, DBV has been having ongoing conversations and exchanges with the FDA regarding elements of our BLA with the intention of ensuring a complete, efficient, and timely review of our upcoming Biologics License Application, the BLA, for the Viaskin…”
Start not stated–present
Last confirmed May 11, 2026
Start not stated–present
Last confirmed May 11, 2026
Biotechnology · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | DBV Technologies S.A. (DBVT) | Chief Executive Officer and Director | $600,000 | $1,472,146 |
| 2023 | DBV Technologies S.A. (DBVT) | Chief Executive Officer and Director | $600,000 | $2,440,486 |
| 2022 | DBV Technologies S.A. (DBVT) | Chief Executive Officer and Director | $600,000 | $2,787,640 |
| 2021 | DBV Technologies S.A. (DBVT) | Chief Executive Officer and Director | $600,000 | $2,430,966 |
| 2020 | DBV Technologies S.A. (DBVT) | Chief Executive Officer and Director | $600,000 | $2,062,135 |
